Global Pharmacogenomics (PGx) Market Research Report 2026(Status and Outlook)

May 2026 | 154 pages | ID: GD7AD1A99A53EN
Bosson Research

Abstracts

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

The global Pharmacogenomics (PGx) market size was estimated at USD 9285.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 9.30% during the forecast period.

This report offers a comprehensive and in-depth analysis of the global Pharmacogenomics (PGx) market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.

The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.

A significant focus of this report lies in the competitive landscape of the global Pharmacogenomics (PGx) market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.

In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Pharmacogenomics (PGx) market.

Global Pharmacogenomics (PGx) Market: Market Segmentation Analysis

This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.

A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.

Key Company

• Abbott Laboratories
• Affymetrix, Inc.
• Assurex Health, Inc
• Astrazeneca
• GeneDX
• Illumina, Inc.
• Laboratory Corporation of America Holdings
• Myriad Genetics, Inc.
• Pathway Genomics
• Pfizer, Inc
• Qiagen, Inc.
• Rocheg
• Teva Pharmaceutical Industries Ltd.
• Thermo Fisher Scientific
• Transgenomic, Inc.

Market Segmentation (by Type)

• Polymerase Chain Reaction (PCR)
• Microarray
• Sequencing
• Other

Market Segmentation (by Application)

• Cardiovascular Diseases (CVD)
• Central Nervous System (CNS)
• Cancer/Oncology
• Infectious Diseases
• Other

Geographic Segmentation

• North America (USA, Canada, Mexico)
• Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
• Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
• South America (Brazil, Argentina, Columbia, Rest of South America)
• The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

• Industry drivers, restraints, and opportunities covered in the study
• Neutral perspective on the market performance
• Recent industry trends and developments
• Competitive landscape & strategies of key players
• Potential & niche segments and regions exhibiting promising growth covered
• Historical, current, and projected market size, in terms of value
• In-depth analysis of the Pharmacogenomics (PGx) Market

Overview of the regional outlook of the Pharmacogenomics (PGx) Market:

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Pharmacogenomics (PGx) Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 shares the main producing countries of Pharmacogenomics (PGx), their output value, profit level, regional supply, production capacity layout, etc. from the supply side.

Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.

Chapter 13 is the main points and conclusions of the report.

Key Reasons to Buy this Report:

• Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
• This enables you to anticipate market changes to remain ahead of your competitors
• You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
• The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
• Provision of market value data for each segment and sub-segment
• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
• The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
• Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
• Provides insight into the market through Value Chain
• Market dynamics scenario, along with growth opportunities of the market in the years to come
• 6-month post-sales analyst support

Contents

1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE

1.1 Market Definition and Statistical Scope of Pharmacogenomics (PGx)
1.2 Key Market Segments
  1.2.1 Pharmacogenomics (PGx) Segment by Type
  1.2.2 Pharmacogenomics (PGx) Segment by Application
1.3 Methodology & Sources of Information
  1.3.1 Research Methodology
  1.3.2 Research Process
  1.3.3 Market Breakdown and Data Triangulation
  1.3.4 Base Year
  1.3.5 Report Assumptions & Caveats

2 PHARMACOGENOMICS (PGX) MARKET OVERVIEW

2.1 Global Market Overview
  2.1.1 Global Pharmacogenomics (PGx) Market Size (M USD) Estimates and Forecasts (2020-2035)
  2.1.2 Global Pharmacogenomics (PGx) Sales Estimates and Forecasts (2020-2035)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region

3 PHARMACOGENOMICS (PGX) MARKET COMPETITIVE LANDSCAPE

3.1 Company Assessment Quadrant
3.2 Global Pharmacogenomics (PGx) Product Life Cycle
3.3 Global Pharmacogenomics (PGx) Sales by Manufacturers (2020-2025)
3.4 Global Pharmacogenomics (PGx) Revenue Market Share by Manufacturers (2020-2025)
3.5 Pharmacogenomics (PGx) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Pharmacogenomics (PGx) Average Price by Manufacturers (2020-2025)
3.7 Manufacturers’ Manufacturing Sites, Areas Served, and Product Types
3.8 Pharmacogenomics (PGx) Market Competitive Situation and Trends
  3.8.1 Pharmacogenomics (PGx) Market Concentration Rate
  3.8.2 Global 5 and 10 Largest Pharmacogenomics (PGx) Players Market Share by Revenue
  3.8.3 Mergers & Acquisitions, Expansion

4 PHARMACOGENOMICS (PGX) INDUSTRY CHAIN ANALYSIS

4.1 Pharmacogenomics (PGx) Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis

5 THE DEVELOPMENT AND DYNAMICS OF PHARMACOGENOMICS (PGX) MARKET

5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
  5.4.1 New Product Developments
  5.4.2 Mergers & Acquisitions
  5.4.3 Expansions
  5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
  5.5.1 Industry Policies Analysis
  5.5.2 Economic Environment Analysis
  5.5.3 Social Environment Analysis
  5.5.4 Technological Environment Analysis
5.6 Global Pharmacogenomics (PGx) Market Porter's Five Forces Analysis
  5.6.1 Global Trade Frictions
  5.6.2 U.S. Tariff Policy – April 2025
  5.6.3 Global Trade Frictions and Their Impacts to Pharmacogenomics (PGx) Market
5.7 ESG Ratings of Leading Companies

6 PHARMACOGENOMICS (PGX) MARKET SEGMENTATION BY TYPE

6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Pharmacogenomics (PGx) Sales Market Share by Type (2020-2025)
6.3 Global Pharmacogenomics (PGx) Market Size by Type (2020-2025)
6.4 Global Pharmacogenomics (PGx) Price by Type (2020-2025)

7 PHARMACOGENOMICS (PGX) MARKET SEGMENTATION BY APPLICATION

7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Pharmacogenomics (PGx) Market Sales by Application (2020-2025)
7.3 Global Pharmacogenomics (PGx) Market Size (M USD) by Application (2020-2025)
7.4 Global Pharmacogenomics (PGx) Sales Growth Rate by Application (2020-2025)

8 PHARMACOGENOMICS (PGX) MARKET SALES BY REGION

8.1 Global Pharmacogenomics (PGx) Sales by Region
  8.1.1 Global Pharmacogenomics (PGx) Sales by Region
  8.1.2 Global Pharmacogenomics (PGx) Sales Market Share by Region
8.2 Global Pharmacogenomics (PGx) Market Size by Region
  8.2.1 Global Pharmacogenomics (PGx) Market Size by Region
  8.2.2 Global Pharmacogenomics (PGx) Market Size by Region
8.3 North America
  8.3.1 North America Pharmacogenomics (PGx) Sales by Country
  8.3.2 North America Pharmacogenomics (PGx) Market Size by Country
  8.3.3 U.S. Market Overview
  8.3.4 Canada Market Overview
  8.3.5 Mexico Market Overview
8.4 Europe
  8.4.1 Europe Pharmacogenomics (PGx) Sales by Country
  8.4.2 Europe Pharmacogenomics (PGx) Market Size by Country
  8.4.3 Germany Market Overview
  8.4.4 France Market Overview
  8.4.5 U.K. Market Overview
  8.4.6 Italy Market Overview
  8.4.7 Spain Market Overview
8.5 Asia Pacific
  8.5.1 Asia Pacific Pharmacogenomics (PGx) Sales by Region
  8.5.2 Asia Pacific Pharmacogenomics (PGx) Market Size by Region
  8.5.3 China Market Overview
  8.5.4 Japan Market Overview
  8.5.5 South Korea Market Overview
  8.5.6 India Market Overview
  8.5.7 Southeast Asia Market Overview
8.6 South America
  8.6.1 South America Pharmacogenomics (PGx) Sales by Country
  8.6.2 South America Pharmacogenomics (PGx) Market Size by Country
  8.6.3 Brazil Market Overview
  8.6.4 Argentina Market Overview
  8.6.5 Columbia Market Overview
8.7 Middle East and Africa
  8.7.1 Middle East and Africa Pharmacogenomics (PGx) Sales by Region
  8.7.2 Middle East and Africa Pharmacogenomics (PGx) Market Size by Region
  8.7.3 Saudi Arabia Market Overview
  8.7.4 UAE Market Overview
  8.7.5 Egypt Market Overview
  8.7.6 Nigeria Market Overview
  8.7.7 South Africa Market Overview

9 PHARMACOGENOMICS (PGX) MARKET PRODUCTION BY REGION

9.1 Global Production of Pharmacogenomics (PGx) by Region(2020-2025)
9.2 Global Pharmacogenomics (PGx) Revenue Market Share by Region (2020-2025)
9.3 Global Pharmacogenomics (PGx) Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Pharmacogenomics (PGx) Production
  9.4.1 North America Pharmacogenomics (PGx) Production Growth Rate (2020-2025)
  9.4.2 North America Pharmacogenomics (PGx) Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Pharmacogenomics (PGx) Production
  9.5.1 Europe Pharmacogenomics (PGx) Production Growth Rate (2020-2025)
  9.5.2 Europe Pharmacogenomics (PGx) Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Pharmacogenomics (PGx) Production (2020-2025)
  9.6.1 Japan Pharmacogenomics (PGx) Production Growth Rate (2020-2025)
  9.6.2 Japan Pharmacogenomics (PGx) Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Pharmacogenomics (PGx) Production (2020-2025)
  9.7.1 China Pharmacogenomics (PGx) Production Growth Rate (2020-2025)
  9.7.2 China Pharmacogenomics (PGx) Production, Revenue, Price and Gross Margin (2020-2025)

10 KEY COMPANIES PROFILE

10.1 Abbott Laboratories
  10.1.1 Abbott Laboratories Basic Information
  10.1.2 Abbott Laboratories Pharmacogenomics (PGx) Product Overview
  10.1.3 Abbott Laboratories Pharmacogenomics (PGx) Product Market Performance
  10.1.4 Abbott Laboratories Business Overview
  10.1.5 Abbott Laboratories SWOT Analysis
  10.1.6 Abbott Laboratories Recent Developments
10.2 Affymetrix, Inc.
  10.2.1 Affymetrix, Inc. Basic Information
  10.2.2 Affymetrix, Inc. Pharmacogenomics (PGx) Product Overview
  10.2.3 Affymetrix, Inc. Pharmacogenomics (PGx) Product Market Performance
  10.2.4 Affymetrix, Inc. Business Overview
  10.2.5 Affymetrix, Inc. SWOT Analysis
  10.2.6 Affymetrix, Inc. Recent Developments
10.3 Assurex Health, Inc
  10.3.1 Assurex Health, Inc Basic Information
  10.3.2 Assurex Health, Inc Pharmacogenomics (PGx) Product Overview
  10.3.3 Assurex Health, Inc Pharmacogenomics (PGx) Product Market Performance
  10.3.4 Assurex Health, Inc Business Overview
  10.3.5 Assurex Health, Inc SWOT Analysis
  10.3.6 Assurex Health, Inc Recent Developments
10.4 Astrazeneca
  10.4.1 Astrazeneca Basic Information
  10.4.2 Astrazeneca Pharmacogenomics (PGx) Product Overview
  10.4.3 Astrazeneca Pharmacogenomics (PGx) Product Market Performance
  10.4.4 Astrazeneca Business Overview
  10.4.5 Astrazeneca Recent Developments
10.5 GeneDX
  10.5.1 GeneDX Basic Information
  10.5.2 GeneDX Pharmacogenomics (PGx) Product Overview
  10.5.3 GeneDX Pharmacogenomics (PGx) Product Market Performance
  10.5.4 GeneDX Business Overview
  10.5.5 GeneDX Recent Developments
10.6 Illumina, Inc.
  10.6.1 Illumina, Inc. Basic Information
  10.6.2 Illumina, Inc. Pharmacogenomics (PGx) Product Overview
  10.6.3 Illumina, Inc. Pharmacogenomics (PGx) Product Market Performance
  10.6.4 Illumina, Inc. Business Overview
  10.6.5 Illumina, Inc. Recent Developments
10.7 Laboratory Corporation of America Holdings
  10.7.1 Laboratory Corporation of America Holdings Basic Information
  10.7.2 Laboratory Corporation of America Holdings Pharmacogenomics (PGx) Product Overview
  10.7.3 Laboratory Corporation of America Holdings Pharmacogenomics (PGx) Product Market Performance
  10.7.4 Laboratory Corporation of America Holdings Business Overview
  10.7.5 Laboratory Corporation of America Holdings Recent Developments
10.8 Myriad Genetics, Inc.
  10.8.1 Myriad Genetics, Inc. Basic Information
  10.8.2 Myriad Genetics, Inc. Pharmacogenomics (PGx) Product Overview
  10.8.3 Myriad Genetics, Inc. Pharmacogenomics (PGx) Product Market Performance
  10.8.4 Myriad Genetics, Inc. Business Overview
  10.8.5 Myriad Genetics, Inc. Recent Developments
10.9 Pathway Genomics
  10.9.1 Pathway Genomics Basic Information
  10.9.2 Pathway Genomics Pharmacogenomics (PGx) Product Overview
  10.9.3 Pathway Genomics Pharmacogenomics (PGx) Product Market Performance
  10.9.4 Pathway Genomics Business Overview
  10.9.5 Pathway Genomics Recent Developments
10.10 Pfizer, Inc
  10.10.1 Pfizer, Inc Basic Information
  10.10.2 Pfizer, Inc Pharmacogenomics (PGx) Product Overview
  10.10.3 Pfizer, Inc Pharmacogenomics (PGx) Product Market Performance
  10.10.4 Pfizer, Inc Business Overview
  10.10.5 Pfizer, Inc Recent Developments
10.11 Qiagen, Inc.
  10.11.1 Qiagen, Inc. Basic Information
  10.11.2 Qiagen, Inc. Pharmacogenomics (PGx) Product Overview
  10.11.3 Qiagen, Inc. Pharmacogenomics (PGx) Product Market Performance
  10.11.4 Qiagen, Inc. Business Overview
  10.11.5 Qiagen, Inc. Recent Developments
10.12 Rocheg
  10.12.1 Rocheg Basic Information
  10.12.2 Rocheg Pharmacogenomics (PGx) Product Overview
  10.12.3 Rocheg Pharmacogenomics (PGx) Product Market Performance
  10.12.4 Rocheg Business Overview
  10.12.5 Rocheg Recent Developments
10.13 Teva Pharmaceutical Industries Ltd.
  10.13.1 Teva Pharmaceutical Industries Ltd. Basic Information
  10.13.2 Teva Pharmaceutical Industries Ltd. Pharmacogenomics (PGx) Product Overview
  10.13.3 Teva Pharmaceutical Industries Ltd. Pharmacogenomics (PGx) Product Market Performance
  10.13.4 Teva Pharmaceutical Industries Ltd. Business Overview
  10.13.5 Teva Pharmaceutical Industries Ltd. Recent Developments
10.14 Thermo Fisher Scientific
  10.14.1 Thermo Fisher Scientific Basic Information
  10.14.2 Thermo Fisher Scientific Pharmacogenomics (PGx) Product Overview
  10.14.3 Thermo Fisher Scientific Pharmacogenomics (PGx) Product Market Performance
  10.14.4 Thermo Fisher Scientific Business Overview
  10.14.5 Thermo Fisher Scientific Recent Developments
10.15 Transgenomic, Inc.
  10.15.1 Transgenomic, Inc. Basic Information
  10.15.2 Transgenomic, Inc. Pharmacogenomics (PGx) Product Overview
  10.15.3 Transgenomic, Inc. Pharmacogenomics (PGx) Product Market Performance
  10.15.4 Transgenomic, Inc. Business Overview
  10.15.5 Transgenomic, Inc. Recent Developments

11 PHARMACOGENOMICS (PGX) MARKET FORECAST BY REGION

11.1 Global Pharmacogenomics (PGx) Market Size Forecast
11.2 Global Pharmacogenomics (PGx) Market Forecast by Region
  11.2.1 North America Market Size Forecast by Country
  11.2.2 Europe Pharmacogenomics (PGx) Market Size Forecast by Country
  11.2.3 Asia Pacific Pharmacogenomics (PGx) Market Size Forecast by Region
  11.2.4 South America Pharmacogenomics (PGx) Market Size Forecast by Country
  11.2.5 Middle East and Africa Forecasted Sales of Pharmacogenomics (PGx) by Country

12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2035)

12.1 Global Pharmacogenomics (PGx) Market Forecast by Type (2026-2035)
  12.1.1 Global Forecasted Sales of Pharmacogenomics (PGx) by Type (2026-2035)
  12.1.2 Global Pharmacogenomics (PGx) Market Size Forecast by Type (2026-2035)
  12.1.3 Global Forecasted Price of Pharmacogenomics (PGx) by Type (2026-2035)
12.2 Global Pharmacogenomics (PGx) Market Forecast by Application (2026-2035)
  12.2.1 Global Pharmacogenomics (PGx) Sales (K Units) Forecast by Application
  12.2.2 Global Pharmacogenomics (PGx) Market Size (M USD) Forecast by Application (2026-2035)

13 CONCLUSION AND KEY FINDINGS

List Of Tables

LIST OF TABLES

Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Global Pharmacogenomics (PGx) Market Size by Type (M USD)
Table 4. Global Pharmacogenomics (PGx) Market Size by Application
Table 5. Pharmacogenomics (PGx) Market Size Comparison by Region (M USD)
Table 6. Global Pharmacogenomics (PGx) Sales (K Units) by Manufacturers (2020-2025)
Table 7. Global Pharmacogenomics (PGx) Sales Market Share by Manufacturers (2020-2025)
Table 8. Global Pharmacogenomics (PGx) Revenue (M USD) by Manufacturers (2020-2025)
Table 9. Global Pharmacogenomics (PGx) Revenue Share by Manufacturers (2020-2025)
Table 10. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pharmacogenomics (PGx) as of 2025)
Table 11. Global Market Pharmacogenomics (PGx) Average Price (USD/Unit) of Key Manufacturers (2020-2025)
Table 12. Manufacturers’ Manufacturing Sites, Areas Served
Table 13. Manufacturers’ Product Type
Table 14. Global Pharmacogenomics (PGx) Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Pharmacogenomics (PGx) Market Challenges
Table 22. Goldman Sachs' forecast real GDP growth rate for 2025-2026
Table 23. S&P Global ' Forecast Real GDP Growth Rate For 2025-2027
Table 24. World Bank ' Forecast Real GDP Growth Rate For 2025-2026
Table 25. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 26. Global Pharmacogenomics (PGx) Sales by Type (K Units)
Table 27. Global Pharmacogenomics (PGx) Market Size by Type (M USD)
Table 28. Global Pharmacogenomics (PGx) Sales (K Units) by Type (2020-2025)
Table 29. Global Pharmacogenomics (PGx) Sales Market Share by Type (2020-2025)
Table 30. Global Pharmacogenomics (PGx) Market Size (M USD) by Type (2020-2025)
Table 31. Global Pharmacogenomics (PGx) Market Share by Type (2020-2025)
Table 32. Global Pharmacogenomics (PGx) Price (USD/Unit) by Type (2020-2025)
Table 33. Global Pharmacogenomics (PGx) Sales (K Units) by Application
Table 34. Global Pharmacogenomics (PGx) Market Size by Application
Table 35. Global Pharmacogenomics (PGx) Sales by Application (2020-2025) & (K Units)
Table 36. Global Pharmacogenomics (PGx) Sales Market Share by Application (2020-2025)
Table 37. Global Pharmacogenomics (PGx) Market Size by Application (2020-2025) & (M USD)
Table 38. Global Pharmacogenomics (PGx) Market Share by Application (2020-2025)
Table 39. Global Pharmacogenomics (PGx) Sales Growth Rate by Application (2020-2025)
Table 40. Global Pharmacogenomics (PGx) Sales by Region (2020-2025) & (K Units)
Table 41. Global Pharmacogenomics (PGx) Sales Market Share by Region (2020-2025)
Table 42. Global Pharmacogenomics (PGx) Market Size by Region (2020-2025) & (M USD)
Table 43. Global Pharmacogenomics (PGx) Market Size by Region (2020-2025)
Table 44. North America Pharmacogenomics (PGx) Sales by Country (2020-2025) & (K Units)
Table 45. North America Pharmacogenomics (PGx) Market Size by Country (2020-2025) & (M USD)
Table 46. Europe Pharmacogenomics (PGx) Sales by Country (2020-2025) & (K Units)
Table 47. Europe Pharmacogenomics (PGx) Market Size by Country (2020-2025) & (M USD)
Table 48. Asia Pacific Pharmacogenomics (PGx) Sales by Region (2020-2025) & (K Units)
Table 49. Asia Pacific Pharmacogenomics (PGx) Market Size by Region (2020-2025) & (M USD)
Table 50. South America Pharmacogenomics (PGx) Sales by Country (2020-2025) & (K Units)
Table 51. South America Pharmacogenomics (PGx) Market Size by Country (2020-2025) & (M USD)
Table 52. Middle East and Africa Pharmacogenomics (PGx) Sales by Region (2020-2025) & (K Units)
Table 53. Middle East and Africa Pharmacogenomics (PGx) Market Size by Region (2020-2025) & (M USD)
Table 54. Global Pharmacogenomics (PGx) Production (K Units) by Region(2020-2025)
Table 55. Global Pharmacogenomics (PGx) Revenue (US$ Million) by Region (2020-2025)
Table 56. Global Pharmacogenomics (PGx) Revenue Market Share by Region (2020-2025)
Table 57. Global Pharmacogenomics (PGx) Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 58. North America Pharmacogenomics (PGx) Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 59. Europe Pharmacogenomics (PGx) Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 60. Japan Pharmacogenomics (PGx) Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 61. China Pharmacogenomics (PGx) Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 62. Abbott Laboratories Basic Information
Table 63. Abbott Laboratories Pharmacogenomics (PGx) Product Overview
Table 64. Abbott Laboratories Pharmacogenomics (PGx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 65. Abbott Laboratories Business Overview
Table 66. Abbott Laboratories SWOT Analysis
Table 67. Abbott Laboratories Recent Developments
Table 68. Affymetrix, Inc. Basic Information
Table 69. Affymetrix, Inc. Pharmacogenomics (PGx) Product Overview
Table 70. Affymetrix, Inc. Pharmacogenomics (PGx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 71. Affymetrix, Inc. Business Overview
Table 72. Affymetrix, Inc. SWOT Analysis
Table 73. Affymetrix, Inc. Recent Developments
Table 74. Assurex Health, Inc Basic Information
Table 75. Assurex Health, Inc Pharmacogenomics (PGx) Product Overview
Table 76. Assurex Health, Inc Pharmacogenomics (PGx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 77. Assurex Health, Inc Business Overview
Table 78. Assurex Health, Inc SWOT Analysis
Table 79. Assurex Health, Inc Recent Developments
Table 80. Astrazeneca Basic Information
Table 81. Astrazeneca Pharmacogenomics (PGx) Product Overview
Table 82. Astrazeneca Pharmacogenomics (PGx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 83. Astrazeneca Business Overview
Table 84. Astrazeneca Recent Developments
Table 85. GeneDX Basic Information
Table 86. GeneDX Pharmacogenomics (PGx) Product Overview
Table 87. GeneDX Pharmacogenomics (PGx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 88. GeneDX Business Overview
Table 89. GeneDX Recent Developments
Table 90. Illumina, Inc. Basic Information
Table 91. Illumina, Inc. Pharmacogenomics (PGx) Product Overview
Table 92. Illumina, Inc. Pharmacogenomics (PGx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 93. Illumina, Inc. Business Overview
Table 94. Illumina, Inc. Recent Developments
Table 95. Laboratory Corporation of America Holdings Basic Information
Table 96. Laboratory Corporation of America Holdings Pharmacogenomics (PGx) Product Overview
Table 97. Laboratory Corporation of America Holdings Pharmacogenomics (PGx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 98. Laboratory Corporation of America Holdings Business Overview
Table 99. Laboratory Corporation of America Holdings Recent Developments
Table 100. Myriad Genetics, Inc. Basic Information
Table 101. Myriad Genetics, Inc. Pharmacogenomics (PGx) Product Overview
Table 102. Myriad Genetics, Inc. Pharmacogenomics (PGx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 103. Myriad Genetics, Inc. Business Overview
Table 104. Myriad Genetics, Inc. Recent Developments
Table 105. Pathway Genomics Basic Information
Table 106. Pathway Genomics Pharmacogenomics (PGx) Product Overview
Table 107. Pathway Genomics Pharmacogenomics (PGx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 108. Pathway Genomics Business Overview
Table 109. Pathway Genomics Recent Developments
Table 110. Pfizer, Inc Basic Information
Table 111. Pfizer, Inc Pharmacogenomics (PGx) Product Overview
Table 112. Pfizer, Inc Pharmacogenomics (PGx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 113. Pfizer, Inc Business Overview
Table 114. Pfizer, Inc Recent Developments
Table 115. Qiagen, Inc. Basic Information
Table 116. Qiagen, Inc. Pharmacogenomics (PGx) Product Overview
Table 117. Qiagen, Inc. Pharmacogenomics (PGx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 118. Qiagen, Inc. Business Overview
Table 119. Qiagen, Inc. Recent Developments
Table 120. Rocheg Basic Information
Table 121. Rocheg Pharmacogenomics (PGx) Product Overview
Table 122. Rocheg Pharmacogenomics (PGx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 123. Rocheg Business Overview
Table 124. Rocheg Recent Developments
Table 125. Teva Pharmaceutical Industries Ltd. Basic Information
Table 126. Teva Pharmaceutical Industries Ltd. Pharmacogenomics (PGx) Product Overview
Table 127. Teva Pharmaceutical Industries Ltd. Pharmacogenomics (PGx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 128. Teva Pharmaceutical Industries Ltd. Business Overview
Table 129. Teva Pharmaceutical Industries Ltd. Recent Developments
Table 130. Thermo Fisher Scientific Basic Information
Table 131. Thermo Fisher Scientific Pharmacogenomics (PGx) Product Overview
Table 132. Thermo Fisher Scientific Pharmacogenomics (PGx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 133. Thermo Fisher Scientific Business Overview
Table 134. Thermo Fisher Scientific Recent Developments
Table 135. Transgenomic, Inc. Basic Information
Table 136. Transgenomic, Inc. Pharmacogenomics (PGx) Product Overview
Table 137. Transgenomic, Inc. Pharmacogenomics (PGx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 138. Transgenomic, Inc. Business Overview
Table 139. Transgenomic, Inc. Recent Developments
Table 140. Global Pharmacogenomics (PGx) Sales Forecast by Region (2026-2035) & (K Units)
Table 141. Global Pharmacogenomics (PGx) Market Size Forecast by Region (2026-2035) & (M USD)
Table 142. North America Pharmacogenomics (PGx) Sales Forecast by Country (2026-2035) & (K Units)
Table 143. North America Pharmacogenomics (PGx) Market Size Forecast by Country (2026-2035) & (M USD)
Table 144. Europe Pharmacogenomics (PGx) Sales Forecast by Country (2026-2035) & (K Units)
Table 145. Europe Pharmacogenomics (PGx) Market Size Forecast by Country (2026-2035) & (M USD)
Table 146. Asia Pacific Pharmacogenomics (PGx) Sales Forecast by Region (2026-2035) & (K Units)
Table 147. Asia Pacific Pharmacogenomics (PGx) Market Size Forecast by Region (2026-2035) & (M USD)
Table 148. South America Pharmacogenomics (PGx) Sales Forecast by Country (2026-2035) & (K Units)
Table 149. South America Pharmacogenomics (PGx) Market Size Forecast by Country (2026-2035) & (M USD)
Table 150. Middle East and Africa Pharmacogenomics (PGx) Sales Forecast by Country (2026-2035) & (Units)
Table 151. Middle East and Africa Pharmacogenomics (PGx) Market Size Forecast by Country (2026-2035) & (M USD)
Table 152. Global Pharmacogenomics (PGx) Sales Forecast by Type (2026-2035) & (K Units)
Table 153. Global Pharmacogenomics (PGx) Market Size Forecast by Type (2026-2035) & (M USD)
Table 154. Global Pharmacogenomics (PGx) Price Forecast by Type (2026-2035) & (USD/Unit)
Table 155. Global Pharmacogenomics (PGx) Sales (K Units) Forecast by Application (2026-2035)
Table 156. Global Pharmacogenomics (PGx) Market Size Forecast by Application (2026-2035) & (M USD)

List Of Figures

LIST OF FIGURES

Figure 1. Product Picture of Pharmacogenomics (PGx)
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Pharmacogenomics (PGx) Market Size (M USD), 2025-2035
Figure 5. Global Pharmacogenomics (PGx) Market Size (M USD) (2020-2035)
Figure 6. Global Pharmacogenomics (PGx) Sales (K Units) & (2020-2035)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Pharmacogenomics (PGx) Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global Pharmacogenomics (PGx) Product Life Cycle
Figure 13. Pharmacogenomics (PGx) Sales Share by Manufacturers in 2025
Figure 14. Global Pharmacogenomics (PGx) Revenue Share by Manufacturers in 2025
Figure 15. Pharmacogenomics (PGx) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2025
Figure 16. Global Market Pharmacogenomics (PGx) Average Price (USD/Unit) of Key Manufacturers in 2025
Figure 17. The Global 5 and 10 Largest Players: Market Share by Pharmacogenomics (PGx) Revenue in 2025
Figure 18. Industry Chain Map of Pharmacogenomics (PGx)
Figure 19. Global Pharmacogenomics (PGx) Market PEST Analysis
Figure 20. Global Pharmacogenomics (PGx) Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global Pharmacogenomics (PGx) Market Share by Type
Figure 27. Sales Market Share of Pharmacogenomics (PGx) by Type (2020-2025)
Figure 28. Sales Market Share of Pharmacogenomics (PGx) by Type in 2025
Figure 29. Market Share of Pharmacogenomics (PGx) by Type (2020-2025)
Figure 30. Market Share of Pharmacogenomics (PGx) by Type in 2025
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global Pharmacogenomics (PGx) Market Share by Application
Figure 33. Global Pharmacogenomics (PGx) Sales Market Share by Application (2020-2025)
Figure 34. Global Pharmacogenomics (PGx) Sales Market Share by Application in 2025
Figure 35. Global Pharmacogenomics (PGx) Market Share by Application (2020-2025)
Figure 36. Global Pharmacogenomics (PGx) Market Share by Application in 2025
Figure 37. Global Pharmacogenomics (PGx) Sales Growth Rate by Application (2020-2025)
Figure 38. Global Pharmacogenomics (PGx) Sales Market Share by Region (2020-2025)
Figure 39. Global Pharmacogenomics (PGx) Market Size by Region (2020-2025)
Figure 40. North America Pharmacogenomics (PGx) Sales and Growth Rate (2020-2025) & (K Units)
Figure 41. North America Pharmacogenomics (PGx) Sales and Growth Rate (2020-2025) & (K Units)
Figure 42. North America Pharmacogenomics (PGx) Sales Market Share by Country in 2024
Figure 43. North America Pharmacogenomics (PGx) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America Pharmacogenomics (PGx) Market Size by Country in 2024
Figure 45. U.S. Pharmacogenomics (PGx) Sales and Growth Rate (2020-2025) & (K Units)
Figure 46. U.S. Pharmacogenomics (PGx) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada Pharmacogenomics (PGx) Sales (K Units) and Growth Rate (2020-2025)
Figure 48. Canada Pharmacogenomics (PGx) Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico Pharmacogenomics (PGx) Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico Pharmacogenomics (PGx) Market Size (Units) and Growth Rate (2020-2025)
Figure 51. Europe Pharmacogenomics (PGx) Sales and Growth Rate (2020-2025) & (K Units)
Figure 52. Europe Pharmacogenomics (PGx) Sales Market Share by Country in 2024
Figure 53. Europe Pharmacogenomics (PGx) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe Pharmacogenomics (PGx) Market Size by Country in 2024
Figure 55. Germany Pharmacogenomics (PGx) Sales and Growth Rate (2020-2025) & (K Units)
Figure 56. Germany Pharmacogenomics (PGx) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France Pharmacogenomics (PGx) Sales and Growth Rate (2020-2025) & (K Units)
Figure 58. France Pharmacogenomics (PGx) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. U.K. Pharmacogenomics (PGx) Sales and Growth Rate (2020-2025) & (K Units)
Figure 60. U.K. Pharmacogenomics (PGx) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy Pharmacogenomics (PGx) Sales and Growth Rate (2020-2025) & (K Units)
Figure 62. Italy Pharmacogenomics (PGx) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain Pharmacogenomics (PGx) Sales and Growth Rate (2020-2025) & (K Units)
Figure 64. Spain Pharmacogenomics (PGx) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific Pharmacogenomics (PGx) Sales and Growth Rate (K Units)
Figure 66. Asia Pacific Pharmacogenomics (PGx) Sales Market Share by Region in 2024
Figure 67. Asia Pacific Pharmacogenomics (PGx) Market Size by Region in 2024
Figure 68. China Pharmacogenomics (PGx) Sales and Growth Rate (2020-2025) & (K Units)
Figure 69. China Pharmacogenomics (PGx) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan Pharmacogenomics (PGx) Sales and Growth Rate (2020-2025) & (K Units)
Figure 71. Japan Pharmacogenomics (PGx) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea Pharmacogenomics (PGx) Sales and Growth Rate (2020-2025) & (K Units)
Figure 73. South Korea Pharmacogenomics (PGx) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India Pharmacogenomics (PGx) Sales and Growth Rate (2020-2025) & (K Units)
Figure 75. India Pharmacogenomics (PGx) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia Pharmacogenomics (PGx) Sales and Growth Rate (2020-2025) & (K Units)
Figure 77. Southeast Asia Pharmacogenomics (PGx) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America Pharmacogenomics (PGx) Sales and Growth Rate (K Units)
Figure 79. South America Pharmacogenomics (PGx) Sales Market Share by Country in 2024
Figure 80. South America Pharmacogenomics (PGx) Market Size and Growth Rate (M USD)
Figure 81. South America Pharmacogenomics (PGx) Market Size by Country in 2024
Figure 82. Brazil Pharmacogenomics (PGx) Sales and Growth Rate (2020-2025) & (K Units)
Figure 83. Brazil Pharmacogenomics (PGx) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina Pharmacogenomics (PGx) Sales and Growth Rate (2020-2025) & (K Units)
Figure 85. Argentina Pharmacogenomics (PGx) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia Pharmacogenomics (PGx) Sales and Growth Rate (2020-2025) & (K Units)
Figure 87. Columbia Pharmacogenomics (PGx) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa Pharmacogenomics (PGx) Sales and Growth Rate (K Units)
Figure 89. Middle East and Africa Pharmacogenomics (PGx) Sales Market Share by Region in 2024
Figure 90. Middle East and Africa Pharmacogenomics (PGx) Market Size and Growth Rate (M USD)
Figure 91. Middle East and Africa Pharmacogenomics (PGx) Market Size by Region in 2024
Figure 92. Saudi Arabia Pharmacogenomics (PGx) Sales and Growth Rate (2020-2025) & (K Units)
Figure 93. Saudi Arabia Pharmacogenomics (PGx) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE Pharmacogenomics (PGx) Sales and Growth Rate (2020-2025) & (K Units)
Figure 95. UAE Pharmacogenomics (PGx) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt Pharmacogenomics (PGx) Sales and Growth Rate (2020-2025) & (K Units)
Figure 97. Egypt Pharmacogenomics (PGx) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria Pharmacogenomics (PGx) Sales and Growth Rate (2020-2025) & (K Units)
Figure 99. Nigeria Pharmacogenomics (PGx) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa Pharmacogenomics (PGx) Sales and Growth Rate (2020-2025) & (K Units)
Figure 101. South Africa Pharmacogenomics (PGx) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global Pharmacogenomics (PGx) Production Market Share by Region (2020-2025)
Figure 103. North America Pharmacogenomics (PGx) Production (K Units) Growth Rate (2020-2025)
Figure 104. Europe Pharmacogenomics (PGx) Production (K Units) Growth Rate (2020-2025)
Figure 105. Japan Pharmacogenomics (PGx) Production (K Units) Growth Rate (2020-2025)
Figure 106. China Pharmacogenomics (PGx) Production (K Units) Growth Rate (2020-2025)
Figure 107. Global Pharmacogenomics (PGx) Sales Forecast by Volume (2020-2035) & (K Units)
Figure 108. Global Pharmacogenomics (PGx) Market Size Forecast by Value (2020-2035) & (M USD)
Figure 109. Global Pharmacogenomics (PGx) Sales Market Share Forecast by Type (2026-2035)
Figure 110. Global Pharmacogenomics (PGx) Market Share Forecast by Type (2026-2035)
Figure 111. Global Pharmacogenomics (PGx) Sales Forecast by Application (2026-2035)
Figure 112. Global Pharmacogenomics (PGx) Market Share Forecast by Application (2026-2035)